Fosun Pharma’s Global Ambitions: Innovation-Driven Expansion in 2025
In the first half of 2025, Fosun Pharma's revenue from innovative drugs rose by 14.3%, with overseas revenue reaching RMB 5,478 million (28.07% of total revenue).13
Achieved multiple overseas licensing deals, including an oral DPP-1 inhibitor for up to US$645 million in August 2025 and a GLP-1 product YP05002 with Pfizer for over USD2 billion in December 2025.125
Products like HANSIZHUANG approved in nearly 40 countries and HANQUYOU in over 50 countries, with global sales of RMB1.4442 billion for HANQUYOU in H1 2025.2
Established sales networks in Africa (40+ countries), Southeast Asia, US generics market, India via Gland Pharma, and a production facility in France; new partnerships in Saudi Arabia.135
Guided by 4IN strategy (Innovation, Internationalization, Integration, Intelligentization), focusing on oncology, immune disorders, ADCs, and emerging modalities like radiopharmaceuticals.34
Invested RMB3.6 billion in technology and innovation in H1 2025, with leadership comments emphasizing global BD and market opportunities.23
Sources:
1. https://en.fosun.com/content/details46_5465.html
2. https://www.prnewswire.com/news-releases/fosun-international-announces-2025-interim-results-steady-growth-in-core-businesses-with-accelerated-innovation-and-globalization-302540012.html
3. https://www.fosunpharma.com/en/content/details37_16824.html
4. https://www.fosunpharma.com/en/content/details37_16931.html